This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

ASCO '13: Array Drug First to be Effective Against Melanoma of the Eye

Stocks in this article: AZN ARRY GSK

CHICAGO ( TheStreet) -- An experimental drug from AstraZeneca (AZN) and Array Biopharma (ARRY) shrank tumors in half of patients with melanoma of the eye and delayed the re-growth of tumors for twice as long as patients treated with temozolomide, a commonly used melanoma drug.

The phase II study of selumetinib, presented at the American Society of Clinical Oncology (ASCO) annual meeting, is the first to ever demonstrate a meaningful clinical benefit for patients with advanced melanoma of the eye.

Selumetinib is a pill which blocks a protein known as MEK used by cancer cells to grow. Array discovered selumetinib and licensed the drug to AstraZeneca in 2003. AstraZeneca is conducting phase II studies of selumetinib in non-small cell lung cancer, pancreatic cancer and thyroid cancer.

Melanoma of the eye is a rare cancer, with about 2,000 cases diagnosed in the U.S. each year. About half of patients develop metastatic disease with survival ranging from nine to 12 months. No currently approved drugs are effective in treating melanoma of the eye, including drugs for skin melanoma.

In the study, 98 patients with metastatic melanoma of the eye were randomized to treatment with selumetinib or temozolomide. Fifteen percent of selumetinib-treated patients achieving major tumor shrinkage while temozolomide produced no tumor shrinkage.

Selumetinib delayed the regrowth of tumors (progression-free survival) by a median of 15.9 weeks compared to 7 weeks for temozolomide.

Median overall survival for selumetinib-treated patients was 10.8 months compared to 9.4 months for temozolomide. The relatively small survival benefit was impacted by temozolomide patients who "crossed over" to receive selumetinib once their tumors started to grow again.

Selumetinib failed to demonstrate significant efficacy in the more widely diagnosed skin melanoma. In a phase II study also being presented at the ASCO meeting, the combination of selumetinib and dacarbazine reduced the risk of death by only 7 percent compared to dacarbazine plus a placebo. The narrow survival edge was not statistically significant.

Earlier this week, a GlaxoSmithKline (GSK) MEK inhibitor known as Mekinist was approved by the FDA for patients with metastatic melanoma with two gene mutations known as BRAF V600E or V600K. Mekinist's approval was based on a pivotal study in which the drug delayed tumor growth by 3.3 months compared to chemotherapy.

AstraZeneca is conducting multiple phase II studies of selumetinib in other forms of cancer.

-- Reported by Adam Feuerstein in Chicago.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs